BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Munari E, Mariotti FR, Quatrini L, Bertoglio P, Tumino N, Vacca P, Eccher A, Ciompi F, Brunelli M, Martignoni G, Bogina G, Moretta L. PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. Int J Mol Sci 2021;22:5123. [PMID: 34066087 DOI: 10.3390/ijms22105123] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 13.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang M, Zhang L, Chang W, Zhang Y. The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes. Front Immunol 2022;13:1096551. [PMID: 36726985 DOI: 10.3389/fimmu.2022.1096551] [Reference Citation Analysis]
2 Javier GC, Alberto I, Azucena GNE, Iván V, Débora M, David P, Laura A, Andrea MS, Esther S, Oleguer C, Paula B, Laura M, Nuria V, Miquel N, Patricia G, Barbara A, Neus B, Tamara S, Manel J, Aleix P, Francesco S. Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study. Cancer Immunol Immunother 2023. [PMID: 36625938 DOI: 10.1007/s00262-022-03360-9] [Reference Citation Analysis]
3 Xu Y, Hao X, Ren Y, Xu Q, Liu X, Song S, Wang Y. Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma. Front Oncol 2022;12:1063423. [PMID: 36686771 DOI: 10.3389/fonc.2022.1063423] [Reference Citation Analysis]
4 Provinciali N, Greppi M, Pesce S, Rutigliani M, Briata IM, Buttiron Webber T, Fava M, DeCensi A, Marcenaro E. Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art. Front Immunol 2022;13:1094017. [PMID: 36601114 DOI: 10.3389/fimmu.2022.1094017] [Reference Citation Analysis]
5 Perez-Santos M, Anaya-Ruiz M, Villafaña-Diaz L, Sánchez Esgua G. Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents. Expert Opin Drug Discov 2022;17:1341-55. [PMID: 36399656 DOI: 10.1080/17460441.2022.2148652] [Reference Citation Analysis]
6 Luo XY, Zhang YM, Zhu RQ, Yang SS, Zhou LF, Zhu HY. Development and validation of novel nomograms to predict survival of patients with tongue squamous cell carcinoma. World J Clin Cases 2022; 10(32): 11726-11742 [DOI: 10.12998/wjcc.v10.i32.11726] [Reference Citation Analysis]
7 Liu XH, Zou QM, Cao JD, Wang ZC. Primary squamous cell carcinoma with sarcomatoid differentiation of the kidney associated with ureteral stone obstruction: A case report . World J Clin Cases 2022; 10(32): 11942-11948 [DOI: 10.12998/wjcc.v10.i32.11942] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Peng J, Zhang J, Zou D, Xiao L, Ma H, Zhang X, Li Y, Han L, Xie B. Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.960459] [Reference Citation Analysis]
9 Waduge P, Tian H, Webster KA, Li W. Profiling disease-selective drug targets: From proteomics to ligandomics. Drug Discov Today 2022;28:103430. [PMID: 36343915 DOI: 10.1016/j.drudis.2022.103430] [Reference Citation Analysis]
10 Munari E, Quatrini L, Ciancaglini C, Eccher A, Bogina G, Moretta L, Mariotti FR. Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells. Semin Immunol 2022;61-64:101660. [PMID: 36370672 DOI: 10.1016/j.smim.2022.101660] [Reference Citation Analysis]
11 Gu P, Ling B, Ma W, Zhang J, Zhang W, Zeng Y, Liu Y, Chi J, Ruan X, Zheng X, Wei S, Gao M. Indoleamine 2,3-dioxygenase 2 immunohistochemical expression in medullary thyroid carcinoma: implications in prognosis and immunomodulatory effects. BMC Cancer 2022;22:1116. [PMID: 36319978 DOI: 10.1186/s12885-022-10173-7] [Reference Citation Analysis]
12 Yaping W, Zhe W, Zhuling C, Ruolei L, Pengyu F, Lili G, Cheng J, Bo Z, Liuyin L, Guangdong H, Yaoling W, Niuniu H, Rui L. The soldiers needed to be awakened: Tumor-infiltrating immune cells. Front Genet 2022;13:988703. [DOI: 10.3389/fgene.2022.988703] [Reference Citation Analysis]
13 Zhou Y, Guan X, Wang S, Sun H, Ma H, Raza F. N6-Methyladenosine (m6A)-Related lncRNAs Are Potential Signatures for Predicting Prognosis and Immune Response in Lung Squamous Cell Carcinoma. Journal of Oncology 2022;2022:1-13. [DOI: 10.1155/2022/5240611] [Reference Citation Analysis]
14 Xu J, Chen S, Liang J, Hao T, Wang H, Liu G, Jin X, Li H, Zhang J, Zhang C, He Y. Schlafen family is a prognostic biomarker and corresponds with immune infiltration in gastric cancer. Front Immunol 2022;13:922138. [DOI: 10.3389/fimmu.2022.922138] [Reference Citation Analysis]
15 Astigiano C, Benzi A, Laugieri ME, Piacente F, Sturla L, Guida L, Bruzzone S, De Flora A. Paracrine ADP Ribosyl Cyclase-Mediated Regulation of Biological Processes. Cells 2022;11:2637. [DOI: 10.3390/cells11172637] [Reference Citation Analysis]
16 Munari E, Querzoli G, Brunelli M, Marconi M, Sommaggio M, Cocchi MA, Martignoni G, Netto GJ, Caliò A, Quatrini L, Mariotti FR, Luchini C, Girolami I, Eccher A, Segala D, Ciompi F, Zamboni G, Moretta L, Bogina G. Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection. Front Immunol 2022;13:954910. [DOI: 10.3389/fimmu.2022.954910] [Reference Citation Analysis]
17 Marletta S, Fusco N, Munari E, Luchini C, Cimadamore A, Brunelli M, Querzoli G, Martini M, Vigliar E, Colombari R, Girolami I, Pagni F, Eccher A. Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. JPM 2022;12:1073. [DOI: 10.3390/jpm12071073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ren Y, He S, Feng S, Yang W. A Prognostic Model for Colon Adenocarcinoma Patients Based on Ten Amino Acid Metabolism Related Genes. Front Public Health 2022;10:916364. [PMID: 35712285 DOI: 10.3389/fpubh.2022.916364] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Liu W, Huo G, Chen P. Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis. Front Immunol 2022;13:909027. [DOI: 10.3389/fimmu.2022.909027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Lucia F, Geier M, Schick U, Bourbonne V. Narrative Review of Synergistics Effects of Combining Immunotherapy and Stereotactic Radiation Therapy. Biomedicines 2022;10:1414. [PMID: 35740435 DOI: 10.3390/biomedicines10061414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Paces W, Ergon E, Bueche E, Young GD, Adisetiyo V, Luengo C, James M, Caldwell C, Miller D, Wambaugh M, Metcalf G, Gianani R. A digital assay for programmed death-ligand 1 (22C3) quantification combined with immune cell recognition algorithms in non-small cell lung cancer. Sci Rep 2022;12:9745. [PMID: 35697702 DOI: 10.1038/s41598-022-12697-1] [Reference Citation Analysis]
22 Sunpaweravong P, Thongwatchara P, Chotipanvithayakul R, Sangkhathat S, Thongsuksai P. Expression and Prognostic Significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 Among Patients With Non-Small Cell Lung Cancer. Clin Med Insights Oncol 2022;16:11795549221092747. [PMID: 35479767 DOI: 10.1177/11795549221092747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Tong H, Sun J, Fang J, Zhang M, Liu H, Xia R, Zhou W, Liu K, Chen X. A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts Tumor Immune Profiles in Non-Small Cell Lung Cancer: A Retrospective Multicohort Study. Front Immunol 2022;13:859323. [DOI: 10.3389/fimmu.2022.859323] [Reference Citation Analysis]
24 Emaldi M, Nunes-Xavier CE. B7-H4 Immune Checkpoint Protein Affects Viability and Targeted Therapy of Renal Cancer Cells. Cells 2022;11:1448. [PMID: 35563753 DOI: 10.3390/cells11091448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Liu B, Ji Q, Cheng Y, Liu M, Zhang B, Mei Q, Liu D, Zhou S. Biomimetic GBM-targeted drug delivery system boosting ferroptosis for immunotherapy of orthotopic drug-resistant GBM. J Nanobiotechnology 2022;20:161. [PMID: 35351131 DOI: 10.1186/s12951-022-01360-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Tartour E, Johannes L. STxB as an Antigen Delivery Tool for Mucosal Vaccination. Toxins 2022;14:202. [DOI: 10.3390/toxins14030202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
27 Kgokolo MCM, Anderson K, Siwele SC, Steel HC, Kwofie LLI, Sathekge MM, Meyer PWA, Rapoport BL, Anderson R. Elevated Levels of Soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and Systemic Inflammatory Stress as Potential Contributors to Immune Suppression and Generalized Tumorigenesis in a Cohort of South African Xeroderma Pigmentosum Patients. Front Oncol 2022;12:819790. [PMID: 35223501 DOI: 10.3389/fonc.2022.819790] [Reference Citation Analysis]
28 Guerini Rocco E, Eccher A, Girolami I, Graziano P, Fontanini G, Vigliar E, Troncone G, Barberis M, Morbini P, Martini M. Concordance between Three PD-L1 Immunohistochemical Assays in Head and Neck Squamous Cell Carcinoma (HNSCC) in a Multicenter Study. Diagnostics 2022;12:477. [DOI: 10.3390/diagnostics12020477] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Luo Y, Chen R, Ning Z, Fu N, Xie M. Identification of a Four-Gene Signature for Determining the Prognosis of Papillary Thyroid Carcinoma by Integrated Bioinformatics Analysis. IJGM 2022;Volume 15:1147-60. [DOI: 10.2147/ijgm.s346058] [Reference Citation Analysis]
30 Kumar S, Pandey M, Mir IA, Mukhopadhyay A, Sharawat SK, Jain D, Saikia J, Malik PS, Kumar S, Mohan A. Evaluation of the programmed death-ligand 1 mRNA expression and immunopositivity and their correlation with survival outcomes in Indian lung cancer patients. Hum Cell 2021. [PMID: 34786661 DOI: 10.1007/s13577-021-00647-4] [Reference Citation Analysis]
31 Goh SK, Cox DRA, Weickhardt A, Muralidharan V, Perini MV. Pancreatic mass in a patient undergoing immunotherapy for metastatic renal cell carcinoma: dilemmas in management. ANZ J Surg 2021. [PMID: 34775660 DOI: 10.1111/ans.17363] [Reference Citation Analysis]
32 Yang Y, Huang H, Li T, Gao Q, Song Y, Wang Z. Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma. Front Immunol 2021;12:728750. [PMID: 34764951 DOI: 10.3389/fimmu.2021.728750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Paolino G, Pantanowitz L, Barresi V, Pagni F, Munari E, Moretta L, Brunelli M, Bariani E, Vigliar E, Pisapia P, Malapelle U, Troncone G, Girolami I, Eccher A. PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy. Pathol Res Pract 2021;226:153605. [PMID: 34530257 DOI: 10.1016/j.prp.2021.153605] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
34 Adorisio S, Cannarile L, Delfino DV, Ayroldi E. Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused? Cells 2021;10:2333. [PMID: 34571982 DOI: 10.3390/cells10092333] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
35 Nie D, Xue Y, Fang Q, Cheng J, Li B, Wang D, Li C, Gui S, Zhang Y, Zhao P. Immune Checkpoints: Therapeutic Targets for Pituitary Tumors. Dis Markers 2021;2021:5300381. [PMID: 34447484 DOI: 10.1155/2021/5300381] [Reference Citation Analysis]
36 Louis W, Guorong L, Anne-emmanuelle B, Claude L. Flow cytometry potential applications in characterizing solid tumors main phenotype, heterogeneity and circulating cells. Arch Pathol Clin Res 2021;5:010-015. [DOI: 10.29328/journal.apcr.1001022] [Reference Citation Analysis]